Ahluwalia Jusleen, Wan Joy, Lee Diana H, Treat James, Yan Albert C
Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Pediatr Dermatol. 2014 Nov-Dec;31(6):664-9. doi: 10.1111/pde.12481.
Administration of intravenous immunoglobulin (IVIG) to patients with Stevens-Johnson syndrome (SJS) has been controversial. The objective of this study was to evaluate the effectiveness of IVIG, systemic corticosteroids, or both in treating Mycoplasma pneumoniae-associated SJS (mpSJS). Retrospective series of 10 pediatric mpSJS cases were stratified into four treatment groups: IVIG alone, IVIG and systemic corticosteroids together, systemic corticosteroids alone, and supportive care. The efficacy of therapy was evaluated on the basis of several proxies of disease severity, including hospital length of stay (LOSt ) and number of febrile days (Febt ) after initiation of therapy. Patients treated with IVIG alone had a longer LOSt and more Febt , despite different baseline characteristics, than patients treated with supportive therapy. Of patients who received IVIG, 50% were treated with corticosteroids concurrently and had similar characteristics of disease severity but showed a non-statistically significant trend toward shorter LOSt and fewer Febt than those who received IVIG alone. A patient treated with corticosteroids alone had the shortest LOSt in this series. Therefore treatment with IVIG alone was associated with a more severe disease course than supportive therapy, although causality cannot be inferred given possible confounding by indication. When systemic corticosteroids were used alone or in conjunction with IVIG, hospital LOSt and Febt trended lower than with the use of IVIG alone, although disease severity at baseline was similar between those treated with IVIG and corticosteroids concurrently and those treated with IVIG alone. It was thus concluded that treatment with systemic corticosteroids as monotherapy or in combination with IVIG may be preferable to IVIG alone. Further large-scale studies are warranted to evaluate this hypothesis.
给史蒂文斯-约翰逊综合征(SJS)患者静脉注射免疫球蛋白(IVIG)一直存在争议。本研究的目的是评估IVIG、全身性皮质类固醇或两者联合治疗肺炎支原体相关SJS(mpSJS)的有效性。对10例儿童mpSJS病例的回顾性系列研究被分为四个治疗组:单独使用IVIG、IVIG与全身性皮质类固醇联合使用、单独使用全身性皮质类固醇以及支持性治疗。根据疾病严重程度的几个指标评估治疗效果,包括治疗开始后的住院时间(LOSt)和发热天数(Febt)。尽管基线特征不同,但单独接受IVIG治疗的患者比接受支持性治疗的患者有更长的LOSt和更多的Febt。在接受IVIG治疗的患者中,50%同时接受了皮质类固醇治疗,疾病严重程度特征相似,但与单独接受IVIG治疗的患者相比,LOSt缩短和Febt减少的趋势无统计学意义。在该系列中,单独接受皮质类固醇治疗的患者LOSt最短。因此,尽管由于可能的指征混杂无法推断因果关系,但单独使用IVIG治疗与比支持性治疗更严重的病程相关。当单独使用全身性皮质类固醇或与IVIG联合使用时,住院LOSt和Febt的趋势低于单独使用IVIG时,尽管同时接受IVIG和皮质类固醇治疗的患者与单独接受IVIG治疗的患者在基线时的疾病严重程度相似。因此得出结论,全身性皮质类固醇单药治疗或与IVIG联合治疗可能比单独使用IVIG更可取。有必要进行进一步的大规模研究来评估这一假设。